Longevity Peptide Stack: What People Actually Use

What "longevity peptide stack" actually means

"Longevity peptides" is not a defined pharmacological category — it's a loose umbrella term for compounds that practitioners and biohackers use with the goal of slowing aspects of biological aging or improving long-term health markers. The compounds in this category vary widely in mechanism, evidence base, and regulatory status.

Searches for "longevity peptides" have grown rapidly over the last 18 months as the GLP-1 wave normalized injectable protocols and as the longevity field (David Sinclair, Peter Attia, Bryan Johnson) drove mainstream interest. This article maps what people actually mean when they say "longevity stack" — not as endorsement, but to help you have an informed conversation with your provider.

Compounds commonly grouped as "longevity peptides"

Note that GLP-1 agonists are arguably the strongest evidence-based "longevity" compound on this list — SELECT trial showed cardiovascular mortality reduction from semaglutide. They get less attention in "longevity peptide" conversations because they're already mainstream, but the data on them is more robust than most compounds explicitly marketed as longevity peptides.

What a "longevity stack" typically looks like

A common multi-compound longevity protocol described in practitioner reports and biohacker communities:

• NAD+ or NMN/NR precursor: Daily oral or weekly SubQ/IV NAD+, or a daily oral precursor (NMN, NR)
• GH secretagogue: CJC-1295/Ipamorelin daily, fasted state, for GH axis support
• Recovery peptide: BPC-157 daily for tissue repair / inflammation
• Metabolic compound: Low-dose semaglutide or tirzepatide for metabolic health (often "microdosing" — sub-therapeutic doses)
• Optional: Thymosin Alpha-1 (immune), Epitalon (telomerase) on various cadences

This is a specific class of multi-compound protocol — easily 4–5 compounds with different cadences, half-lives, and timing requirements. Tracking such a stack is exactly the use case My Pep Calc was built for.

The evidence reality: GLP-1s vs. everything else

A common pattern in longevity conversations: niche peptides (Epitalon, Thymosin Alpha-1, BPC-157 used for "anti-aging") get more discussion than they deserve based on their actual evidence base, while GLP-1 drugs — which have produced the most robust cardiovascular and mortality trial data of any compound in this group — get less attention because they're "boring" or "for diabetics."

If you are evaluating compounds for longevity goals, the evidence ranks roughly:

1. GLP-1 agonists (semaglutide, tirzepatide) — Phase 3 mortality data exists
2. NAD+ adjacent (NMN, NR) — emerging human trials, mechanism well-established
3. GH secretagogues (CJC/Ipa) — pituitary effects characterized; longevity inference is extrapolation
4. Tissue repair peptides (BPC-157, TB-500) — animal data, very limited human trials
5. Niche peptides (Epitalon, Thymosin Alpha-1, others) — variable, often non-Western evidence

This isn't a recommendation to choose one over another. It's a reminder that "everyone is doing it" is not the same as "the evidence supports doing it."

The "microdosing" pattern with GLP-1s

A protocol increasingly seen in longevity contexts: low-dose semaglutide (e.g., 0.25 mg/week, the standard starting dose for diabetes/obesity) used not for weight loss but for metabolic / cardiovascular benefits at sub-therapeutic doses.

The clinical evidence for "microdose GLP-1" specifically is much thinner than for therapeutic doses. The cardiovascular mortality benefits in trials were at therapeutic doses, not microdoses. Whether sub-therapeutic doses preserve any meaningful fraction of those benefits is not well established. Discuss with your provider before pursuing this.

NAD+ specifically: it's not a peptide

NAD+ (nicotinamide adenine dinucleotide) is a cofactor, not a peptide. It often gets bundled into "peptide stack" conversations because it's commonly used as a SubQ injection or IV in longevity-focused clinics, and it's frequently stacked with peptides. But pharmacologically, it's a different category.

For tracking purposes, NAD+ behaves like any other regular SubQ injection — log dose, date, site. See the NAD+ tracking primer for the full dosing and tracking detail.

Why this stack is hard to track without dedicated tools

A 5-compound longevity stack might involve:

• Daily NAD+ (or NMN oral)
• Daily fasted CJC/Ipamorelin (morning AND/OR evening)
• Daily BPC-157 (any time)
• Weekly semaglutide microdose
• Periodic Thymosin Alpha-1 (variable cadence, often pulsed)

Five compounds, five different cadences, three different timing requirements (fasted CJC/Ipa, food-flexible BPC and NAD+, weekly sema). The combinations compound: deciding whether to inject CJC/Ipa or NAD+ first in the morning, how to schedule weekly semaglutide on top of daily compounds, when to add or cycle Thymosin.

My Pep Calc tracks each compound independently with its own cadence, dose log, and half-life curve. The half-life chart shows your full protocol on one timeline so you can see what's active when.

What we are not doing in this article

We are not endorsing longevity peptide protocols, recommending specific stacks, or making claims about life extension. The compounds discussed have varying evidence bases, and the strongest evidence (GLP-1 agonists for cardiovascular mortality) is for therapeutic doses in indicated patient populations — not for healthy biohackers seeking life extension. Discuss any longevity-oriented protocol with a prescribing provider who knows your specific health context.